Press Release Details

Investor Relations

GoHealth Reports Third Quarter 2022 Results

Nov 10, 2022 at 4:13 PM EST

CHICAGO, Nov. 10, 2022 /PRNewswire/ -- GoHealth, Inc. (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three and nine months ended September 30, 2022.

  • YTD 2022 positive cash flow from operations of $101.9 million compared to negative cash flow from operations of $72.4 million in the prior year period.
  • Third quarter 2022 Medicare Submitted Policies of 132,831 decreased 34% compared to the prior year period. YTD 2022 Medicare Submitted Policies of 611,385 increased 11% compared to the prior year period.
  • Third quarter 2022 net revenue of $133.1 million decreased 37% compared to the prior year period. YTD 2022 net revenue of $562.3 million decreased 8% compared to the prior year period.
  • Third quarter 2022 net loss of $74.7 million compared to a net loss of $55.5 million in the prior year period.  YTD 2022 net loss of $225.6 million compared to a net loss of $102.0 million in the prior year period. 
  • Third quarter 2022 Adjusted EBITDA1 of negative $14.3 million compared to Adjusted EBITDA1 of negative $14.2 million in the prior year period. YTD 2022 Adjusted EBITDA1 of negative $35.0 million compared to Adjusted EBITDA1 of $32.2 million in the prior year period.

"During the third quarter, GoHealth went back to basics with a clear focus on the fundamentals of the business and an aim to put the beneficiary at the center of everything we do. We are making meaningful progress on our transformation through our strategic initiatives and diversification into Encompass. This has materially changed the dynamics of cash flow for our business and we're confident these positive trends will continue as we lean further into our Encompass solution," said Vijay Kotte, GoHealth's Chief Executive Officer.

"The market is in need of unbiased third parties to help support the Medicare shopping and enrollment process. The challenge has been the misaligned rewards structure and the lack of trust in the industry. GoHealth is leveraging our Encompass solution, our health plan relationships, our proprietary technology, and our experienced, high-quality sales agents to solve these industry challenges and act as a trusted partner to beneficiaries," said Kotte.

Mr. Kotte continued, "I believe our end-to-end Encompass solution will be a game changer for our customers, for health plans, and for the financial profile of our business. So far this Annual Enrollment Period, inclusive of a significant adoption of Encompass, we're experiencing a 70% higher conversion rate than we were last year at this time."

"I'm very pleased with the progress we've made in just a few short months. I believe GoHealth is best positioned to seize the opportunities at hand," concluded Mr. Kotte.

Conference Call Details

The Company will host a conference call today, Thursday, November 10, 2022 at 5:00 p.m. (ET) to discuss its financial results.  Participants can pre-register for the conference call at the following link: https://register.vevent.com/register/BIe3f052938613486583fb292fcf47ae56. A live audio webcast of the conference call will be available via GoHealth's Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

About GoHealth, Inc.:

As a leading health insurance marketplace and Medicare-focused digital health company, GoHealth's mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for customers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers. GoHealth combines cutting-edge technology, data science and deep industry expertise to match customers with the healthcare policy and carrier that is right for them. GoHealth has enrolled millions of people in Medicare plans and individual and family plans. For more information, visit https://www.gohealth.com

Investor Relations:
IR@gohealth.com 

Media Relations:
Pressinquiries@gohealth.com 

(1)

Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below.

 

Forward-Looking Statements

This release contains forward-looking statements.  We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding our expected growth, level of cash flow, future capital expenditures and debt service obligations are forward-looking statements.

In some cases, you can identify forward-looking statements by terms, such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although the we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

These forward-looking statements speak only as of the date of this release and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including, but are not limited to, the following:  the marketing and sale of Medicare plans are subject to numerous, complex and frequently changing laws, regulations and guidelines; our business may be harmed if we lose our relationships with carriers or if our relationships with carriers change; our failure to grow our customer base or retain our existing customers; carriers may reduce the commissions paid to us and change their underwriting practices in ways that reduce the number of, or impact the renewal or approval rates of, insurance policies sold through our platform; factors that impact our estimate of LTV (as defined below) may be adversely impacted; our management and independent auditors have identified a material weakness in our internal controls over financial reporting, and we may be unable to develop, implement and maintain appropriate controls in future periods, which may lead to errors or omissions in our financial statements; the potential delisting of our common stock from the Nasdaq Global Market; volatility in general economic conditions, including inflation, interest rates, and other commodity prices and exchange rates may impact our financial position and performance; our ability to borrow under the Credit Agreement is subject to ongoing compliance with a number of financial covenants, affirmative covenants, and other restrictions, which may limit our operations and our ability to take certain actions; we currently depend on a small group of carriers for a substantial portion of our revenue; information technology system failures could interrupt our operations; our ability to sell Medicare-related health insurance plans is largely dependent on our licensed health insurance agents; operating and growing our business may require additional capital; whether our Encompass solution will achieve anticipated benefits; our strategic focus on cash flow optimization may lead to decreased revenue or otherwise adversely affect our business; we may lose key employees or fail to attract qualified employees; our operations may be adversely impacted by a reduction in employee headcount or other similar actions; the Founders (as defined in our Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K")) and Centerbridge (as defined in the 2021 Form 10-K) have significant influence over us, including control over decisions that require the approval of stockholders; and other important factors described in the section titled "Risk Factors" in our 2021 Form 10-K, and the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and in our other filings with the Securities and Exchange Commission.

The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the 2021 Form 10-K, Quarterly Report on Form 10-Q for the first quarter ended March 31, 2022, Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022, and other SEC filings. If one or more events related to these or other risks or uncertainties materialize, or our underlying assumptions prove to be incorrect, actual results may differ materially from what we anticipate. Many of the important factors that will determine these results are beyond our ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Use of Non-GAAP Financial Measures and Key Performance Indicators

In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). These non-GAAP financial measures include net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense ("EBITDA"); Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.

Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for certain items summarized below in this press release.  Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues.

We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA and Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

Glossary

"Adjusted EBITDA" represents, as applicable for the period, EBITDA as further adjusted for certain items summarized below in this press release. 

"Adjusted EBITDA Margin" refers to Adjusted EBITDA divided by net revenues.

"Approved Submissions" refer to Submitted Policies approved by carriers for the identified product during the indicated period.

"LTV Per Approved Submission" refers to the Lifetime Value of Commissions per Approved Submission, which we define as (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Approved Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of commissionable Approved Submissions for such period.

"Submitted Policies" refer to completed applications that, with respect to each such application, the consumer has authorized us to submit to the carrier.

 

The following tables set forth the components of our results of operations for the periods indicated (unaudited):

   

(in thousands, except percentages and per share amounts)

 

Three months ended Sep.
30, 2022

 

Three months ended Sep.
30, 2021

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Commission

 

$      87,058

 

65.4 %

 

$    174,948

 

82.6 %

 

$       (87,890)

 

(50.2) %

Enterprise

 

45,994

 

34.6 %

 

36,786

 

17.4 %

 

9,208

 

25.0 %

Net revenues

 

133,052

 

100.0 %

 

211,734

 

100.0 %

 

(78,682)

 

(37.2) %

Operating expenses:

                       

Cost of revenue

 

48,044

 

36.1 %

 

53,632

 

25.3 %

 

(5,588)

 

(10.4) %

Marketing and advertising

 

22,661

 

17.0 %

 

59,511

 

28.1 %

 

(36,850)

 

(61.9) %

Customer care and enrollment

 

51,153

 

38.4 %

 

86,775

 

41.0 %

 

(35,622)

 

(41.1) %

Technology

 

11,061

 

8.3 %

 

11,651

 

5.5 %

 

(590)

 

(5.1) %

General and administrative

 

25,611

 

19.2 %

 

24,295

 

11.5 %

 

1,316

 

5.4 %

Amortization of intangible assets

 

23,514

 

17.7 %

 

23,514

 

11.1 %

 

 

— %

Operating lease impairment charges

 

350

 

0.3 %

 

1,062

 

0.5 %

 

(712)

 

N/M

Restructuring and other related charges

 

9,797

 

7.4 %

 

 

— %

 

9,797

 

N/M

Total operating expenses

 

192,191

 

144.4 %

 

260,440

 

123.0 %

 

(68,249)

 

(26.2) %

Income (loss) from operations

 

(59,139)

 

(44.4) %

 

(48,706)

 

(23.0) %

 

(10,433)

 

21.4 %

Interest expense

 

15,630

 

11.7 %

 

6,921

 

3.3 %

 

8,709

 

125.8 %

Other (income) expense

 

(115)

 

(0.1) %

 

(30)

 

— %

 

(85)

 

N/M

Income (loss) before income taxes

 

(74,654)

 

(56.1) %

 

(55,597)

 

(26.3) %

 

(19,057)

 

34.3 %

Income tax expense (benefit)

 

 

— %

 

(79)

 

— %

 

79

 

N/M

Net income (loss)

 

$    (74,654)

 

(56.1) %

 

$    (55,518)

 

(26.2) %

 

$       (19,136)

 

34.5 %

Net income (loss) attributable to noncontrolling interests

 

(44,649)

 

(33.6) %

 

(35,278)

 

(16.7) %

 

(9,371)

 

26.6 %

Net income (loss) attributable to GoHealth, Inc.

 

$    (30,005)

 

(22.6) %

 

$    (20,240)

 

(9.6) %

 

$         (9,765)

 

48.2 %

Net income (loss) per share:

                       

Net income (loss) per share of common stock — basic and diluted

 

$        (0.23)

     

$        (0.18)

           

Weighted-average shares of Class A common stock outstanding —
basic and diluted

 

132,378

     

113,938

           

Non-GAAP financial measures:

                       

EBITDA

 

$    (30,959)

     

$     (22,606)

           

Adjusted EBITDA

 

$     (14,327)

     

$     (14,155)

           

Adjusted EBITDA margin

 

(10.8)

%

   

(6.7)

%

         

_________________________

                       

N/M = Not meaningful

                       

 

 

 

(in thousands, except percentages and per share amounts)

 

Nine months ended Sep.
30, 2022

 

Nine months ended Sep.
30, 2021

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Commission

 

$    414,735

 

73.8 %

 

$    496,437

 

81.0 %

 

$       (81,702)

 

(16.5) %

Enterprise

 

147,564

 

26.2 %

 

116,378

 

19.0 %

 

31,186

 

26.8 %

Net revenues

 

562,299

 

100.0 %

 

612,815

 

100.0 %

 

(50,516)

 

(8.2) %

Operating expenses:

                       

Cost of revenue

 

167,041

 

29.7 %

 

139,449

 

22.8 %

 

27,592

 

19.8 %

Marketing and advertising

 

151,408

 

26.9 %

 

169,730

 

27.7 %

 

(18,322)

 

(10.8) %

Customer care and enrollment

 

196,150

 

34.9 %

 

195,796

 

32.0 %

 

354

 

0.2 %

Technology

 

34,569

 

6.1 %

 

33,251

 

5.4 %

 

1,318

 

4.0 %

General and administrative

 

90,859

 

16.2 %

 

69,277

 

11.3 %

 

21,582

 

31.2 %

Amortization of intangible assets

 

70,543

 

12.5 %

 

70,543

 

11.5 %

 

 

— %

Operating lease impairment charges

 

25,345

 

4.5 %

 

1,062

 

0.2 %

 

24,283

 

NM

Restructuring and other related charges

 

11,872

 

2.1 %

 

 

— %

 

11,872

 

NM

Total operating expenses

 

747,787

 

133.0 %

 

679,108

 

110.8 %

 

68,679

 

10.1 %

Income (loss) from operations

 

(185,488)

 

(33.0) %

 

(66,293)

 

(10.8) %

 

(119,195)

 

179.8 %

Interest expense

 

39,752

 

7.1 %

 

23,886

 

3.9 %

 

15,866

 

66.4 %

Loss on extinguishment of debt

 

 

— %

 

11,935

 

1.9 %

 

(11,935)

 

N/M

Other (income) expense

 

(65)

 

— %

 

27

 

— %

 

(92)

 

(340.7) %

Income (loss) before income taxes

 

(225,175)

 

(40.0) %

 

(102,141)

 

(16.7) %

 

(123,034)

 

120.5 %

Income tax expense (benefit)

 

472

 

0.1 %

 

(142)

 

— %

 

614

 

N/M

Net income (loss)

 

$   (225,647)

 

(40.1) %

 

$   (101,999)

 

(16.6) %

 

$     (123,648)

 

121.2 %

Net loss attributable to noncontrolling interests

 

(138,340)

 

(24.6) %

 

(67,668)

 

(11.0) %

 

$        (70,672)

 

104.4 %

Net loss attributable to GoHealth, Inc.

 

$    (87,307)

 

(15.5) %

 

$    (34,331)

 

(5.6) %

 

$       (52,976)

 

154.3 %

Net income (loss) per share:

                       

Net income (loss) per share of common stock — basic and diluted

 

$        (0.70)

     

$        (0.33)

           

Weighted-average shares of Class A common stock outstanding —
basic and diluted

 

124,401

     

102,939

           

Non-GAAP financial measures:

                       

EBITDA

 

$   (104,999)

     

$       (1,080)

           

Adjusted EBITDA

 

$     (34,995)

     

$      32,197

           

Adjusted EBITDA margin

 

(6.2)

%

   

5.3

%

         

_________________________

                       

NM = Not meaningful

                       

 

 

The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):

   

Three months ended Sep. 30,

(in thousands)

 

2022

 

2021

Net revenues

 

$    133,052

 

$    211,734

Net income (loss)

 

(74,654)

 

(55,518)

Interest expense

 

15,630

 

6,921

Income tax expense (benefit)

 

 

(79)

Depreciation and amortization expense

 

28,065

 

26,070

EBITDA

 

(30,959)

 

(22,606)

Restructuring and other related charges (1)

 

9,797

 

Share-based compensation expense (2)

 

6,456

 

7,389

Operating lease impairment charges (3)

 

350

 

1,062

Professional services (4)

 

29

 

Adjusted EBITDA

 

$     (14,327)

 

$     (14,155)

Adjusted EBITDA margin

 

(10.8) %

 

(6.7) %

         
                     

(1)

Represents employee termination benefits and other associated costs related to restructuring activities.

(2)

Represents non-cash share-based compensation expense relating to equity awards, as well share-based compensation expense relating to liability classified awards that will be settled in cash.

(3)

Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values.

(4)

Represents costs associated with non-recurring consulting fees and other professional services.

 

   

Nine months ended Sep. 30,

(in thousands)

 

2022

 

2021

Net revenues

 

$    562,299

 

$    612,815

Net income (loss)

 

(225,647)

 

(101,999)

Interest expense

 

39,752

 

23,886

Income tax expense (benefit)

 

472

 

(142)

Depreciation and amortization expense

 

80,424

 

77,175

EBITDA

 

(104,999)

 

(1,080)

Share-based compensation expense (1)

 

25,868

 

20,100

Operating lease impairment charges (2)

 

25,345

 

1,062

Restructuring and other related charges (3)

 

11,872

 

Professional services (4)

 

3,979

 

Severance costs (5)

 

2,940

 

Loss on extinguishment of debt (6)

 

 

11,935

Legal fees (7)

 

 

180

Adjusted EBITDA

 

$     (34,995)

 

$      32,197

Adjusted EBITDA margin

 

(6.2) %

 

5.3 %

         
                     

(1)

Represents non-cash share-based compensation expense relating to equity awards, as well share-based compensation expense relating to liability classified awards that will be settled in cash.

(2)

Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values.

(3)

Represents employee termination benefits and other associated costs related to restructuring activities.

(4)

Represents costs associated with non-recurring consulting fees and other professional services.

(5)

Represents costs associated with the termination of employment and associated fees unrelated to restructuring activities.

(6)

Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

(7)

Represents non-recurring legal fees unrelated to our core operations.

 

The following table summarizes share-based compensation expense by operating function for the periods indicated (unaudited):

 
   

Three months ended Sep. 30,

 

Nine months ended Sep. 30,

(in thousands)

 

2022

 

2021

 

2022

 

2021

Marketing and advertising

 

$             556

 

$             698

 

$          1,212

 

$          1,462

Customer care and enrollment

 

738

 

957

 

1,993

 

2,796

Technology

 

884

 

910

 

2,493

 

2,791

General and administrative

 

4,277

 

4,824

 

20,170

 

13,051

Total share-based compensation expense

 

$          6,456

 

$          7,389

 

$         25,868

 

$         20,100

 

The following table sets forth our balance sheets for the periods indicated (unaudited):

 

(in thousands, except per share amounts)

 

Sep. 30, 2022

 

Dec. 31, 2021

Assets

       

Current assets:

       

Cash and cash equivalents

 

$           215,403

 

$             84,361

Accounts receivable, net of allowance for doubtful accounts of $271 in 2022 and $558 in 2021

 

4,835

 

17,276

Commissions receivable - current

 

217,937

 

268,663

Prepaid expense and other current assets

 

29,972

 

58,695

Total current assets

 

468,147

 

428,995

Commissions receivable - non-current

 

959,105

 

993,844

Operating lease ROU asset

 

21,436

 

23,462

Other long-term assets

 

1,932

 

3,608

Property, equipment, and capitalized software, net

 

26,930

 

24,273

Intangible assets, net

 

524,126

 

594,669

Total assets

 

$         2,001,676

 

$         2,068,851

Liabilities and Stockholders' Equity

       

Current liabilities:

       

Accounts payable

 

$               9,370

 

$             39,843

Accrued liabilities

 

32,316

 

52,788

Commissions payable - current

 

69,501

 

104,160

Short-term operating lease liability

 

9,381

 

6,126

Deferred revenue

 

114,181

 

536

Current portion of long-term debt

 

5,270

 

5,270

Other current liabilities

 

15,402

 

8,344

Total current liabilities

 

255,421

 

217,067

Non-current liabilities:

       

Commissions payable - non-current

 

305,909

 

274,403

Long-term operating lease liability

 

38,671

 

19,776

Long-term debt, net of current portion

 

660,387

 

665,115

Other non-current liabilities

 

3,624

 

Total non-current liabilities

 

1,008,591

 

959,294

Commitments and Contingencies (Note 11)

       

Series A redeemable convertible preferred stock — $0.0001 par value; 50 shares authorized; 50 shares issued and
outstanding at September 30, 2022.  No shares issued and outstanding as of December 31, 2021. Liquidation preference
of $1,001 per share at September 30, 2022.

 

48,426

 

Series A-1 redeemable convertible preferred stock— $0.0001 par value; 200 shares authorized; no shares issued and
outstanding at September 30, 2022 and December 31, 2021.

 

 

Stockholders' equity:

       

Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 133,462 and 115,487 shares issued;
133,271 and 115,487 shares outstanding at September 30, 2022 and December 31, 2021, respectively.

 

13

 

11

Class B common stock – $0.0001 par value; 578,192 and 587,360 shares authorized; 196,184 and 205,352 shares
issued and outstanding at September 30, 2022 and December 31, 2021, respectively.

 

20

 

21

Preferred stock – $0.0001 par value; 20,000 shares authorized (including 50 shares of Series A redeemable
convertible preferred stock authorized  and 200 shares of Series A-1 redeemable convertible preferred stock
authorized); 50 shares issued and outstanding at September 30, 2022 and no shares issued and outstanding at
December 31, 2021.

 

 

Treasury stock – at cost; 191 shares of Class A common stock at September 30, 2022

 

(345)

 

Additional paid-in capital

 

621,118

 

561,447

Accumulated other comprehensive income (loss)

 

(171)

 

(59)

Accumulated deficit

 

(295,691)

 

(208,317)

Total stockholders' equity attributable to GoHealth, Inc.

 

324,944

 

353,103

Non-controlling interests

 

364,294

 

539,387

Total stockholders' equity

 

689,238

 

892,490

Total liabilities, redeemable convertible preferred stock and stockholders' equity

 

$        2,001,676

 

$        2,068,851

 

The following table sets forth our statements of cash flows for the periods indicated (unaudited):

 
   

Nine months ended Sep.
30,

(in thousands)

 

2022

 

2021

Operating Activities

       

Net loss

 

$     (225,647)

 

$     (101,999)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

       

Share-based compensation

 

22,776

 

20,100

Depreciation and amortization

 

9,881

 

6,632

Amortization of intangible assets

 

70,543

 

70,543

Amortization of debt discount and issuance costs

 

2,163

 

1,696

Loss on extinguishment of debt

 

 

11,935

Operating lease impairment charges

 

25,345

 

1,062

Non-cash restructuring charges

 

976

 

Non-cash lease expense

 

4,064

 

3,765

Other non-cash items

 

(517)

 

(607)

Changes in assets and liabilities:

       

Accounts receivable

 

12,852

 

6,173

Commissions receivable

 

85,522

 

(160,982)

Prepaid expenses and other assets

 

29,608

 

10,471

Accounts payable

 

(30,573)

 

18,298

Accrued liabilities

 

(20,818)

 

5,693

Deferred revenue

 

113,645

 

(175)

Commissions payable

 

(3,153)

 

36,233

Operating lease liabilities

 

(5,885)

 

(3,678)

Other liabilities

 

11,121

 

2,421

Net cash provided by (used in) operating activities

 

101,903

 

(72,419)

Investing Activities

       

Purchases of property, equipment and software

 

(12,096)

 

(19,269)

Net cash used in investing activities

 

(12,096)

 

(19,269)

Financing Activities

       

Proceeds from sale of Series A redeemable convertible preferred stock

 

50,000

 

Issuance cost payments from issuance of Series A redeemable convertible preferred stock

 

(1,641)

 

Proceeds from borrowings

 

 

335,000

Repayment of borrowings

 

(3,953)

 

(297,903)

Call premium paid for debt extinguishment

 

 

(5,910)

Debt issuance cost payments

 

(2,763)

 

(1,608)

Principal payments under finance lease obligations

 

(103)

 

(231)

Cash received on advancement to NVX Holdings, Inc.

 

 

3,395

Net cash (used in) provided by financing activities

 

41,540

 

32,743

Effect of exchange rate changes on cash and cash equivalents

 

(305)

 

(68)

Increase (decrease) in cash and cash equivalents

 

131,042

 

(59,013)

Cash and cash equivalents at beginning of period

 

84,361

 

144,234

Cash and cash equivalents at end of period

 

$      215,403

 

$        85,221

Supplemental Disclosure of Cash Flow Information

       

Non-cash investing and financing activities:

       

Purchases of property, equipment and software included in accounts payable

 

$             100

 

$          2,734

 

The following tables set forth operating segment results for the periods indicated (unaudited):

 

(in thousands, except percentages)

 

Three months ended Sep.
30, 2022

 

Three months ended Sep.
30, 2021

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Medicare - Internal

 

$         79,266

 

59.6 %

 

$       158,605

 

75.0 %

 

$       (79,339)

 

(50.0) %

Medicare - External

 

49,793

 

37.4 %

 

46,237

 

21.8 %

 

3,556

 

7.7 %

IFP and Other - Internal

 

3,459

 

2.6 %

 

5,742

 

2.7 %

 

(2,283)

 

(39.8) %

IFP and Other - External

 

534

 

0.4 %

 

1,150

 

0.5 %

 

(616)

 

(53.6) %

Net revenues

 

133,052

 

100.0 %

 

211,734

 

100.0 %

 

(78,682)

 

(37.2) %

Segment profit (loss):

                       

Medicare - Internal

 

2,609

 

2.0 %

 

(4,126)

 

(1.9) %

 

6,735

 

(163.2) %

Medicare - External

 

(2,201)

 

(1.7) %

 

1,866

 

0.9 %

 

(4,067)

 

(218.0) %

IFP and Other - Internal

 

496

 

0.4 %

 

2,186

 

1.0 %

 

(1,690)

 

(77.3) %

IFP and Other - External

 

(576)

 

(0.4) %

 

(330)

 

(0.2) %

 

(246)

 

74.5 %

Segment profit (loss)

 

328

 

0.2 %

 

(404)

 

(0.2) %

 

732

 

(181.2) %

Corporate expense

 

25,806

 

19.4 %

 

23,726

 

11.2 %

 

2,080

 

8.8 %

Amortization of intangible assets

 

23,514

 

17.7 %

 

23,514

 

11.1 %

 

 

— %

Operating lease impairment charges

 

350

 

0.3 %

 

1,062

 

0.5 %

 

(712)

 

N/M

Restructuring and other related charges

 

9,797

 

7.4 %

 

 

— %

 

9,797

 

N/M

Interest expense

 

15,630

 

11.7 %

 

6,921

 

3.3 %

 

8,709

 

125.8 %

Other (income) expense

 

(115)

 

(0.1) %

 

(30)

 

— %

 

(85)

 

283.3 %

Income (loss) before income taxes

 

$        (74,654)

 

(56.1) %

 

$        (55,597)

 

(26.3) %

 

$        (19,057)

 

34.3 %

_________________________

N/M = Not meaningful

 

   

Nine months ended Sep.
30, 2022

 

Nine months ended Sep.
30, 2021

       

(in thousands, except percentages)

 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Medicare - Internal

 

$       386,796

 

68.8 %

 

$       476,391

 

77.7 %

 

$       (89,595)

 

(18.8) %

Medicare - External

 

161,382

 

28.7 %

 

117,116

 

19.1 %

 

44,266

 

37.8 %

IFP and Other - Internal

 

11,904

 

2.1 %

 

13,505

 

2.2 %

 

(1,601)

 

(11.9) %

IFP and Other - External

 

2,217

 

0.4 %

 

5,803

 

0.9 %

 

(3,586)

 

(61.8) %

Net revenues

 

562,299

 

100.0 %

 

612,815

 

100.0 %

 

(50,516)

 

(8.2) %

Segment profit (loss):

                       

Medicare - Internal

 

26,408

 

4.7 %

 

73,574

 

12.0 %

 

(47,166)

 

(64.1) %

Medicare - External

 

(15,629)

 

(2.8) %

 

(453)

 

(0.1) %

 

(15,176)

 

3350.1 %

IFP and Other - Internal

 

2,668

 

0.5 %

 

657

 

0.1 %

 

2,011

 

306.1 %

IFP and Other - External

 

(1,245)

 

(0.2) %

 

(227)

 

— %

 

(1,018)

 

448.5 %

Segment profit (loss)

 

12,202

 

2.2 %

 

73,551

 

12.0 %

 

(61,349)

 

(83.4) %

Corporate expense

 

89,930

 

16.0 %

 

68,239

 

11.1 %

 

21,691

 

31.8 %

Amortization of intangible assets

 

70,543

 

12.5 %

 

70,543

 

11.5 %

 

 

— %

Operating lease impairment charges

 

25,345

 

4.5 %

 

1,062

 

0.2 %

 

24,283

 

N/M

Restructuring and other related charges

 

11,872

 

2.1 %

 

 

— %

 

11,872

 

N/M

Loss on extinguishment of debt

 

 

— %

 

11,935

 

1.9 %

 

(11,935)

 

N/M

Interest expense

 

39,752

 

7.1 %

 

23,886

 

3.9 %

 

15,866

 

66.4 %

Other (income) expense

 

(65)

 

— %

 

27

 

— %

 

(92)

 

(340.7) %

Income (loss) before income taxes

 

$      (225,175)

 

(40.0) %

 

$      (102,141)

 

(16.7) %

 

$      (123,034)

 

120.5 %

_________________________

N/M = Not meaningful

 

The following table presents the number of Submitted Policies by product for the Medicare segments for the three and nine months ended September 30, 2022 and 2021, for those submissions that are commissionable (compensated through commissions received from carriers):

   
   

Three months ended Sep. 30,

 

Nine months ended Sep. 30,

Medicare - Total Commissionable Submitted Policies

 

2022

 

2021

 

2022

 

2021

Medicare Advantage

 

123,523

 

195,414

 

577,139

 

521,451

Medicare Supplement

 

113

 

751

 

809

 

2,877

Prescription Drug Plans

 

4,025

 

2,740

 

15,485

 

7,707

Total Medicare

 

127,661

 

198,905

 

593,433

 

532,035

 

The following tables present the number of Approved Submissions by product relating to commissionable policies for the Medicare segments for three and nine months ended September 30, 2022 and 2021. Only commissionable policies are used to calculate LTV.

   
   

Three months ended Sep. 30,

 

Nine months ended Sep. 30,

Medicare - Internal Commissionable Approved Submissions

 

2022

 

2021

 

2022

 

2021

Medicare Advantage

 

51,848

 

145,619

 

334,361

 

395,804

Medicare Supplement

 

31

 

183

 

249

 

702

Prescription Drug Plans

 

1,223

 

2,208

 

6,096

 

6,525

Total Medicare

 

53,102

 

148,010

 

340,706

 

403,031

 

   
   

Three months ended Sep. 30,

 

Nine months ended Sep. 30,

Medicare - External Commissionable Approved Submissions

 

2022

 

2021

 

2022

 

2021

Medicare Advantage

 

62,928

 

47,488

 

218,371

 

121,179

Medicare Supplement

 

14

 

427

 

279

 

1,823

Prescription Drug Plans

 

2,761

 

191

 

8,874

 

716

Total Medicare

 

65,703

 

48,106

 

227,524

 

123,718

 

The following table presents the LTV per Approved Submission by product for the Medicare segments for the three and nine months ended September 30, 2022 and 2021:

   
   

Three months ended Sep. 30,

 

Nine months ended Sep. 30,

LTV per Approved Submission

 

2022

 

2021

 

2022

 

2021

Medicare Advantage

 

$           771

 

$           917

 

$           754

 

$           874

Medicare Supplement

 

$           733

 

$           874

 

$           826

 

$           834

Prescription Drug Plans

 

$           200

 

$           215

 

$           202

 

$           215

 

The following table presents the number of Submitted Policies by product for the Medicare segments for the three and nine months ended September 30, 2022 and 2021, for those submissions that are non-commissionable (compensated via hourly fees and enrollment fees) and do not result in commission revenue:

   
   

Three months ended Sep. 30,

 

Nine months ended Sep. 30,

Medicare - Total Non-Commissionable Submitted Policies

 

2022

 

2021

 

2022

 

2021

Medicare Advantage

 

2,631

 

1,532

 

9,868

 

10,703

Medicare Supplement

 

1,805

 

1,327

 

5,790

 

5,019

Prescription Drug Plans

 

734

 

542

 

2,294

 

2,218

Total Medicare

 

5,170

 

3,401

 

17,952

 

17,940

 

 

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gohealth-reports-third-quarter-2022-results-301675048.html

SOURCE GoHealth, Inc.

Our Awards